Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Design, synthesis and characterization of a highly effective inhibitor for analog-sensitive (as) kinases.

Klein M, Morillas M, Vendrell A, Brive L, Gebbia M, Wallace IM, Giaever G, Nislow C, Posas F, Grøtli M.

PLoS One. 2011;6(6):e20789. doi: 10.1371/journal.pone.0020789. Epub 2011 Jun 17.

2.

Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology.

Zhang C, Lopez MS, Dar AC, Ladow E, Finkbeiner S, Yun CH, Eck MJ, Shokat KM.

ACS Chem Biol. 2013 Sep 20;8(9):1931-8. doi: 10.1021/cb400376p. Epub 2013 Jul 23.

3.

Design, synthesis, and characterization of a highly effective Hog1 inhibitor: a powerful tool for analyzing MAP kinase signaling in yeast.

Dinér P, Veide Vilg J, Kjellén J, Migdal I, Andersson T, Gebbia M, Giaever G, Nislow C, Hohmann S, Wysocki R, Tamás MJ, Grøtli M.

PLoS One. 2011;6(5):e20012. doi: 10.1371/journal.pone.0020012. Epub 2011 May 31.

4.

Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.

Řezníčková E, Weitensteiner S, Havlíček L, Jorda R, Gucký T, Berka K, Bazgier V, Zahler S, Kryštof V, Strnad M.

Chem Biol Drug Des. 2015 Dec;86(6):1528-40. doi: 10.1111/cbdd.12618. Epub 2015 Sep 16.

PMID:
26198005
5.

The logic and design of analog-sensitive kinases and their small molecule inhibitors.

Lopez MS, Kliegman JI, Shokat KM.

Methods Enzymol. 2014;548:189-213. doi: 10.1016/B978-0-12-397918-6.00008-2. Review.

PMID:
25399647
6.

A chemical switch for inhibitor-sensitive alleles of any protein kinase.

Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, Blethrow J, Shimizu E, Tsien JZ, Schultz PG, Rose MD, Wood JL, Morgan DO, Shokat KM.

Nature. 2000 Sep 21;407(6802):395-401.

PMID:
11014197
7.

Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).

Reddy MV, Akula B, Jatiani S, Vasquez-Del Carpio R, Billa VK, Mallireddigari MR, Cosenza SC, Venkata Subbaiah DR, Bharathi EV, Pallela VR, Ramkumar P, Jain R, Aggarwal AK, Reddy EP.

Bioorg Med Chem. 2016 Feb 15;24(4):521-44. doi: 10.1016/j.bmc.2015.11.045. Epub 2015 Dec 1.

PMID:
26762835
8.

Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk).

Mott BT, Tanega C, Shen M, Maloney DJ, Shinn P, Leister W, Marugan JJ, Inglese J, Austin CP, Misteli T, Auld DS, Thomas CJ.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6700-5. doi: 10.1016/j.bmcl.2009.09.121. Epub 2009 Oct 3.

9.

NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.

Beria I, Bossi RT, Brasca MG, Caruso M, Ceccarelli W, Fachin G, Fasolini M, Forte B, Fiorentini F, Pesenti E, Pezzetta D, Posteri H, Scolaro A, Re Depaolini S, Valsasina B.

Bioorg Med Chem Lett. 2011 May 15;21(10):2969-74. doi: 10.1016/j.bmcl.2011.03.054. Epub 2011 Mar 21.

PMID:
21470862
10.

Design and use of analog-sensitive protein kinases.

Blethrow J, Zhang C, Shokat KM, Weiss EL.

Curr Protoc Mol Biol. 2004 May;Chapter 18:Unit 18.11. doi: 10.1002/0471142727.mb1811s66.

PMID:
18265343
11.

Application of a peptide-based assay to characterize inhibitors targeting protein kinases from yeast.

Veide Vilg J, Dahal S, Ljungdahl T, Grøtli M, Tamás MJ.

Curr Genet. 2014 Aug;60(3):193-200. doi: 10.1007/s00294-014-0424-3. Epub 2014 Mar 19.

PMID:
24643376
12.

Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.

Chen DX, Huang J, Liu M, Xu YG, Jiang C.

Arch Pharm (Weinheim). 2015 Jan;348(1):2-9. doi: 10.1002/ardp.201400294. Epub 2014 Nov 27.

PMID:
25430493
13.

Design, synthesis and efficacy of novel G protein-coupled receptor kinase 2 inhibitors.

Carotenuto A, Cipolletta E, Gomez-Monterrey I, Sala M, Vernieri E, Limatola A, Bertamino A, Musella S, Sorriento D, Grieco P, Trimarco B, Novellino E, Iaccarino G, Campiglia P.

Eur J Med Chem. 2013 Nov;69:384-92. doi: 10.1016/j.ejmech.2013.08.039. Epub 2013 Sep 13.

PMID:
24077529
14.

Staurosporine-derived inhibitors broaden the scope of analog-sensitive kinase technology.

Lopez MS, Choy JW, Peters U, Sos ML, Morgan DO, Shokat KM.

J Am Chem Soc. 2013 Dec 4;135(48):18153-9. doi: 10.1021/ja408704u. Epub 2013 Nov 20.

15.

Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.

Koeberle SC, Fischer S, Schollmeyer D, Schattel V, Grütter C, Rauh D, Laufer SA.

J Med Chem. 2012 Jun 28;55(12):5868-77. doi: 10.1021/jm300327h. Epub 2012 Jun 15.

PMID:
22676210
16.

SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.

Heron NM, Anderson M, Blowers DP, Breed J, Eden JM, Green S, Hill GB, Johnson T, Jung FH, McMiken HH, Mortlock AA, Pannifer AD, Pauptit RA, Pink J, Roberts NJ, Rowsell S.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1320-3. Epub 2005 Dec 5.

PMID:
16337122
17.

Synthesis and structure based optimization of 2-(4-phenoxybenzoyl)-5-hydroxyindole as a novel CaMKII inhibitor.

Komiya M, Asano S, Koike N, Koga E, Igarashi J, Nakatani S, Isobe Y.

Bioorg Med Chem. 2012 Dec 1;20(23):6840-7. doi: 10.1016/j.bmc.2012.09.048. Epub 2012 Oct 2.

PMID:
23088910
18.

Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.

Kwarcinski FE, Fox CC, Steffey ME, Soellner MB.

ACS Chem Biol. 2012 Nov 16;7(11):1910-7. doi: 10.1021/cb300337u. Epub 2012 Sep 5.

19.

Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity.

Islam I, Bryant J, Chou YL, Kochanny MJ, Lee W, Phillips GB, Yu H, Adler M, Whitlow M, Ho E, Lentz D, Polokoff MA, Subramanyam B, Wu JM, Zhu D, Feldman RI, Arnaiz DO.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8. Epub 2007 Apr 27.

PMID:
17531483
20.

Structure-activity relationship study of acridine analogs as haspin and DYRK2 kinase inhibitors.

Cuny GD, Robin M, Ulyanova NP, Patnaik D, Pique V, Casano G, Liu JF, Lin X, Xian J, Glicksman MA, Stein RL, Higgins JM.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3491-4.

Supplemental Content

Support Center